PR Newswire Clinical TrialsOriginal article
Remepy Welcomes Pharma R&D Leader, Eran Harary, MD, as Chief Medical Officer, to Advance Hybrid Drug™ Pipeline
Phase 3Hybrid Drug™Positive
AI Analysis
Summary
Remepy appointed Eran Harary, MD, former SVP of R&D at Teva Pharmaceuticals, as Chief Medical Officer to lead advancement of its Hybrid Drug pipeline, with Phase III initiation for the Parkinson's disease candidate underway.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Phase III initiation announced
Importance:4/10
Sentiment:
0.40
management_appointmentphase_3_initiationparkinson's_diseaseexecutive_hire
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 16, 2026 11:30 AM